Free tool
FAERS Monitor: Tafinlar
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217514 or its brand name (Tafinlar, Dabrafenib Mesylate). Reports on generic versions are filed under their own applications.
Reports
21,157
Serious
15,709
74% of reports
Hospitalization
5,907
Death reported
4,427
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pyrexia4,146
- death2,899
- malignant neoplasm progression1,771
- fatigue1,445
- nausea1,414
- chills1,343
- rash1,189
- vomiting995
- diarrhoea988
- headache750
- asthenia733
- malaise628
- decreased appetite592
- arthralgia590
- visual impairment550
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2013 | 415 |
| 2014 | 730 |
| 2015 | 1,704 |
| 2016 | 1,382 |
| 2017 | 1,636 |
| 2018 | 2,134 |
| 2019 | 2,338 |
| 2020 | 2,056 |
| 2021 | 2,057 |
| 2022 | 1,877 |
| 2023 | 1,774 |
| 2024 | 1,275 |
| 2025 | 1,103 |
| 2026 | 675 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,033,002 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| malignant neoplasm progressionSignal | 1,771 | 17.5 | 16.7 | 27,151 |
| pyrexiaSignal | 4,146 | 12.0 | 11.7 | 42,167 |
| chillsSignal | 1,343 | 11.5 | 10.9 | 12,800 |
| visual impairmentSignal | 550 | 4.4 | 4.1 | 1,458 |
| deathSignal | 2,899 | 3.4 | 3.2 | 4,973 |
| rashSignal | 1,189 | 2.7 | 2.6 | 1,311 |
| decreased appetiteSignal | 592 | 2.5 | 2.3 | 555 |
| vomitingSignal | 995 | 2.1 | 2.0 | 589 |
| asthenia | 733 | 1.9 | 1.8 | 338 |
| fatigue | 1,445 | 1.8 | 1.8 | 581 |
| nausea | 1,414 | 1.8 | 1.7 | 498 |
| diarrhoea | 988 | 1.5 | 1.4 | 182 |
| malaise | 628 | 1.4 | 1.3 | 80 |
| arthralgia | 590 | 1.4 | 1.3 | 72 |
| headache | 750 | 1.2 | 1.1 | 23 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.